George D. Cresswell

George D. Cresswell

Auto-generated profile, based on publicly available information

George D. Cresswell

Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
TWThomas B. K. Watkins
Thomas B. K. Watkins
ELEmilia L. Lim
Emilia L. Lim
MPMarina Petkovic
Marina Petkovic
SESergi Elizalde
Sergi Elizalde
ABAnd Nicolai J. Birkbak
And Nicolai J. Birkbak
CSCharles Swanton
Charles Swanton

26 October 2022 in Nature
Verified
Journal Article
Open access
PDF file
JHJacob Househam
Jacob Househam
THTimon Heide
Timon Heide
GCGeorge D. Cresswell
George D. Cresswell
ISInmaculada Spiteri
Inmaculada Spiteri
CKChris Kimberley
Chris Kimberley
TGTrevor Graham
Trevor Graham
Genetic and epigenetic variation, together with transcriptional plasticity, contribute to intratumour heterogeneity1. The interplay of these biological processes and their respective contributions to tumour evolution remain unknown. Here we show that intratumour genetic ancestry only infrequently affects gene expression traits and subclonal evolution in colorectal cancer (CRC). Using spatially resolved paired whole-genome and transcriptome sequencing, we find that the majority of intratumour variation in gene expression is not strongly heritable but rather ‘plastic’. Somatic expression quantitative trait loci analysis identified a number of putative genetic controls of expression by cis-acting coding and non-coding mutations, the majority of which were clonal within a tumour, alongside frequent structural alterations. Consistently, computational inference on the spatial patterning of tumour phylogenies finds that a considerable proportion of CRCs did not show evidence of subclonal selection, with only a subset of putative genetic drivers associated with subclone expansions. Spatial intermixing of clones is common, with some tumours growing exponentially and others only at the periphery. Together, our data suggest that most genetic intratumour variation in CRC has no major phenotypic consequence and that transcriptional plasticity is, instead, widespread within a tumour.

2 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GCGiulio Caravagna
Giulio Caravagna
THTimon Heide
Timon Heide
MWMarc J. Williams
Marc J. Williams
LZLuis Zapata
Luis Zapata
DNDaniel Nichol
Daniel Nichol
ASAndrea Sottoriva
Andrea Sottoriva

26 October 2022 in Nature
Verified
Journal Article
Open access
PDF file
THTimon Heide
Timon Heide
JHJacob Househam
Jacob Househam
GCGeorge D. Cresswell
George D. Cresswell
ISInmaculada Spiteri
Inmaculada Spiteri
CLClaire Lynn
Claire Lynn
ASAndrea Sottoriva
Andrea Sottoriva
Colorectal malignancies are a leading cause of cancer-related death1 and have undergone extensive genomic study2,3. However, DNA mutations alone do not fully explain malignant transformation4–7. Here we investigate the co-evolution of the genome and epigenome of colorectal tumours at single-clone resolution using spatial multi-omic profiling of individual glands. We collected 1,370 samples from 30 primary cancers and 8 concomitant adenomas and generated 1,207 chromatin accessibility profiles, 527 whole genomes and 297 whole transcriptomes. We found positive selection for DNA mutations in chromatin modifier genes and recurrent somatic chromatin accessibility alterations, including in regulatory regions of cancer driver genes that were otherwise devoid of genetic mutations. Genome-wide alterations in accessibility for transcription factor binding involved CTCF, downregulation of interferon and increased accessibility for SOX and HOX transcription factor families, suggesting the involvement of developmental genes during tumourigenesis. Somatic chromatin accessibility alterations were heritable and distinguished adenomas from cancers. Mutational signature analysis showed that the epigenome in turn influences the accumulation of DNA mutations. This study provides a map of genetic and epigenetic tumour heterogeneity, with fundamental implications for understanding colorectal cancer biology.

21 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Ahmet AcarAhmet Acar
Ahmet Acar
DNDaniel Nichol
Daniel Nichol
JFJavier Fernández-Mateos
Javier Fernández-Mateos
GCGeorge D. Cresswell
George D. Cresswell
IBIros Barozzi
Iros Barozzi
ASAndrea Sottoriva
Andrea Sottoriva
Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 108–109 cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance.

25 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBenjamin Werner
Benjamin Werner
JCJack Case
Jack Case
MWMarc J. Williams
Marc J. Williams
KCKetevan Chkhaidze
Ketevan Chkhaidze
DTDaniel Temko
Daniel Temko
ASAndrea Sottoriva
Andrea Sottoriva
Both normal tissue development and cancer growth are driven by a branching process of cell division and mutation accumulation that leads to intra-tissue genetic heterogeneity. However, quantifying somatic evolution in humans remains challenging. Here, we show that multi-sample genomic data from a single time point of normal and cancer tissues contains information on single-cell divisions. We present a new theoretical framework that, applied to whole-genome sequencing data of healthy tissue and cancer, allows inferring the mutation rate and the cell survival/death rate per division. On average, we found that cells accumulate 1.14 mutations per cell division in healthy haematopoiesis and 1.37 mutations per division in brain development. In both tissues, cell survival was maximal during early development. Analysis of 131 biopsies from 16 tumours showed 4 to 100 times increased mutation rates compared to healthy development and substantial inter-patient variation of cell survival/death rates.